immunology
-
Apogee Therapeutics to Host Conference Call on July 7, 2025, to Discuss Phase 2 APEX Trial Part A 16-Week Data for APG777 in Moderate-to-Severe Atopic Dermatitis
Apogee Therapeutics will announce pivotal 16-week data from its Phase 2 APEX trial for APG777, a novel inflation drug. The data, expected on July 7, 2025, could reveal differentiated efficacy and new dosing regimens for conditions like atopic dermatitis, asthma, and COPD. The company will host a conference call to discuss the findings.
